Is There a Correlation Between Berger Disease and Bone Lesions?
Yes, there is a clear correlation between IgA nephropathy (Berger disease) and bone lesions, but this relationship is indirect—mediated through chronic kidney disease (CKD) progression rather than being a direct manifestation of IgAN itself.
The Mechanistic Link
When IgA nephropathy progresses to CKD stages 3-5, patients develop CKD-mineral and bone disorder (CKD-MBD), which causes multiple bone pathologies 1. The bone lesions are not caused by IgA deposition in bone tissue, but rather by the metabolic derangements that occur as kidney function declines.
Key Bone Manifestations in CKD from IgAN:
High-turnover bone disease (osteitis fibrosa cystica):
- Occurs with secondary hyperparathyroidism when PTH levels exceed 400 pg/mL
- Characterized by increased osteoclasts, osteoblasts, abnormal bone resorption, and marrow fibrosis
- Presents with bone pain, pathological fractures, and skeletal deformities 1
Low-turnover/adynamic bone disease:
- Increasingly common, now the predominant form in many dialysis centers
- Associated with PTH levels below 100 pg/mL in stage 5 CKD
- Results in 4-fold increased hip fracture risk compared to general population
- Predisposes to metastatic calcification and calciphylaxis 1
Mixed uremic osteodystrophy:
- Combination of mineralization defects and hyperparathyroid changes
- Represents intermediate pathology on the bone disease spectrum 1
Osteomalacia:
- Caused by aluminum toxicity (from aluminum-based phosphate binders), vitamin D deficiency, or hypophosphatemia
- Characterized by defective mineralization of osteoid 1
Clinical Manifestations
Patients with IgAN who progress to advanced CKD develop 1, 2:
- Bone demineralization and decreased trabeculation
- Decreased cortical bone thickness
- Ground-glass appearance on radiographs
- Radiolucent giant cell and fibrocystic lesions
- Lytic bone areas
- Pathological fractures with minimal trauma
- Jaw fractures and abnormal healing after dental extractions
- Metastatic soft-tissue calcifications
Diagnostic Approach
When to suspect bone disease in IgAN patients:
- CKD stage 3 or higher (eGFR <60 mL/min)
- Elevated PTH: >70 pg/mL (stage 3) or >110 pg/mL (stage 4) 1
- Unexplained bone pain, fractures, or elevated bone alkaline phosphatase 1
Diagnostic workup:
- Biochemical monitoring (first-line): Serum calcium, phosphorus, intact PTH, 25-hydroxyvitamin D, bone alkaline phosphatase 3
- Bone biopsy with double tetracycline labeling (gold standard) indicated for 1:
- Pathological fractures
- PTH 100-500 pg/mL with unexplained hypercalcemia or severe bone pain
- Suspected aluminum bone disease
- DEXA scan: For patients with fractures or osteoporosis risk factors 1
- Plain radiographs: Not for bone disease assessment, but useful for detecting vascular calcification 1
Critical Clinical Pitfall
Do not assume bone lesions in IgAN patients are directly caused by IgA deposition. Unlike IgA vasculitis (Henoch-Schönlein purpura), IgAN does not cause primary bone or joint pathology 4, 5. The bone disease develops secondary to CKD progression and requires CKD-MBD management, not immunosuppression targeting IgA production.
Management Implications
Treatment focuses on CKD-MBD management 1, 3:
- For high-turnover disease: Dietary phosphate restriction, phosphate binders, calcitriol or analogs (doxercalciferol, paricalcitol)
- For adynamic bone disease: Reduce calcium-based binders and vitamin D to allow PTH rise 1
- For all patients: Target blood pressure ≤120/70 mmHg, proteinuria <0.5 g/day, optimize vitamin D status 4
The bone complications correlate with CKD severity and duration, not with IgAN disease activity itself. Histologic evidence shows 84% of CKD patients have bone disorders by stage 5 2. Therefore, all IgAN patients progressing beyond CKD stage 3 require systematic bone metabolism monitoring and preventive interventions to reduce fracture risk and improve quality of life.